http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201718608-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-695 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2016-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7709a21d26dc4e6edf3c675d5acde73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09deffd3cd7212a1346f8f35872c23b9 |
| publicationDate | 2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201718608-A |
| titleOfInvention | Antimony-containing compound for anti-hepatitis C virus infection |
| abstract | The present invention provides a hydrazine-containing compound for anti-hepatitis C virus infection, and particularly relates to a novel compound having the HCV NS5A protease inhibitory activity as shown in Formula I, and pharmaceutically acceptable salts, hydrates, solvates thereof, Prodrugs or stereoisomers and mixtures thereof, methods for their preparation, and pharmaceutical compositions thereof. The invention also relates to the use of the compounds, and pharmaceutically acceptable salts, hydrates, solvates, prodrugs or stereoisomers thereof, and mixtures thereof, and pharmaceutical compositions thereof, for the treatment of hepatitis C virus infection. □ |
| priorityDate | 2015-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 322.